Are you or your loved ones suffering from multiple myeloma?

You may be eligible to participate in a multiple myeloma clinical trial.

Are you or your loved ones suffering from multiple myeloma? You may be eligible to participate in a multiple myeloma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Recruiting for this study? Get access to patient recruitment tools.
Multiple Myeloma in Philadelphia PA
NCT02863991 | Phase 1 phase 2 | Interventional
Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Are you or your loved ones suffering from multiple myeloma?

You may be eligible to participate in a multiple myeloma clinical trial.

Are you or your loved ones suffering from multiple myeloma? You may be eligible to participate in a multiple myeloma clinical trial.

Recruiting

Male & Female

18 +

years old

This study is looking to recruit 42 Participants

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

Where you'll go

Selected location

Fox Chase Cancer Center

Fox Chase Cancer Center Change

333 Cottman Avenue, Philadelphia, PA, USA 19111

Carlyn Tan, MD 888-369-2427

Map | Learn more
Available locations
The Mount Sinai Medical Center

The Mount Sinai Medical Center

Recruiting New York, NY, USA 10029-6574

Interested in participating?
Selected location

Fox Chase Cancer Center

333 Cottman Avenue, Philadelphia, PA, USA 19111

Carlyn Tan, MD 888-369-2427


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.